[{"id":"4dba1395-427b-4b7f-9979-50fbb27251ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805956","created_at":"2023-04-10T14:03:09.469Z","updated_at":"2024-07-02T16:35:51.054Z","phase":"Phase 1/2","brief_title":"IMM2902 in Patients With Advanced Solid Tumors Expressing HER2","source_id_and_acronym":"NCT05805956","lead_sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vislarafusp-alfa (IMM2902)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-04-10"},{"id":"0af73023-ed28-45c4-906b-d0d628d0643e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076591","created_at":"2021-10-13T16:58:19.177Z","updated_at":"2024-07-02T16:35:52.034Z","phase":"Phase 1","brief_title":"IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors","source_id_and_acronym":"NCT05076591","lead_sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vislarafusp-alfa (IMM2902)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-29"}]